Zhan Xu

Dr. Zhan Xu


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
FWF Wang
F Wang
DWDinglan Wu
Dinglan Wu
ZXZhan Xu
Zhan Xu
JCJianxiang Chen
Jianxiang Chen
JZJiye Zhang
Jiye Zhang
WWWeifu Wang
Weifu Wang
Human bladder cancer is one of the common malignant tumors, and it mainly occurs in men. miR-182-5p, a member of miR-183 family, acts as tumor suppressor or oncogene in various kinds of tumors. In this study, we first investigate that the absence of miR-182-5p in human bladder cancer promotes tumor growth by regulating the expression of Cofilin 1, an actin modulating-protein. Human bladder tumor tissue specimens were collected to detect the expression of miR-182-5p and Cofilin 1 by qRT-PCR. Luciferase activity assay was performed to demonstrate the regulation of Cofilin 1 mRNA 3′UTR by miR-182-5p. Then, cell experiments were performed to analysis the effect of miR-182-5p/Cofilin 1 pathway on tumor cell proliferation, migration, invasion and colony forming efficiency. Finally, xenograft tumor models were established to evaluate the role of miR-182-5p in tumorigenesis abilities in vivo. qRT-PCR and Western blotting analysis showed that Cofilin 1 expression was up-regulated in both bladder cancer tissues and cell lines compared with normal. Luciferase activity assay showed that miR-182-5p specifically targets Cofilin 1 mRNA 3′UTR and represses the expression of Cofilin 1. Also, miR-182-5p inhibited bladder tumor cell proliferation, migration, invasion and colony forming efficiency. Furthermore, xenograft tumor model assay showed that miR-182-5p plays a negative role in bladder cancer tumorigenesis abilities in vivo. Present results suggest that miR-182-5p could inhibit human bladder tumor growth by repressing Cofilin 1 expression. Our findings may provide a new horizon for exploring therapeutic target of bladder cancer.

21 December 2022 in BMC Urology
Verified
Journal Article
Open access
PDF file
HZHuacai Zhu
Huacai Zhu
BLBangfeng Liu
Bangfeng Liu
MKMehmet Ali Karagöz
Mehmet Ali Karagöz
GYGaoyuanzhi Yue
Gaoyuanzhi Yue
YLYeci Lei
Yeci Lei
YLYongda Liu
Yongda Liu
Day-surgery percutaneous nephrolithotomy (PCNL) is being developed quickly but some potential factors are affecting the recovery process. This study is aim to analyze the reasons and risk factors for delayed discharge after day-surgery PCNL. The data of 205 patients who accepted day-surgery PCNL in our institution between January 2018 and February 2020 were analyzed, retrospectively. Univariate and multivariate logistic regression analysis were used to analyze the risk factors for delayed discharge. Besides, the nomogram prediction model was established by the multivariable logistic regression analysis. The rate of delayed discharge was 14.6%. Independent risk factors for delayed discharge were larger stone burden (odds ratio [OR] = 3.814, P = 0.046), positive urine nitrite (OR = 1.001, P = 0.030), longer duration of surgery (OR = 1.020, P = 0.044), multiple nephrostomy tubes (OR = 4.282, P = 0.008). The five main reasons that caused delayed discharge included psychological reasons, pain, bleeding, urosepsis, and urine leakage. This study identified some independent risk factors for a hospital length of stay longer than 24 h. Patients with larger renal stones or positive urine nitrite may be at increased risk of delayed discharge after day-surgery PCNL. Reducing surgery time and nephrostomy tubes will help to facilitate recovery.

14 March 2024 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
WWWei Wei
Wei Wei
MCMing Chen
Ming Chen
LXLe Xie
Le Xie
YMYuan Mai
Yuan Mai
HZHuacai Zhu
Huacai Zhu
ZXZhan Xu
Zhan Xu

20 December 2023 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
FLFu-Xiang Lin
Fu-Xiang Lin
ZXZhan Xu
Zhan Xu

28 May 2025 in Urology Case Reports
Verified
Journal Article
Open access
JWJunjun Wu
Junjun Wu
LWLei Wang
Lei Wang
PZPengpeng Zhao
Pengpeng Zhao
FLFuxiang Lin
Fuxiang Lin
ZXZhan Xu
Zhan Xu
Primary squamous cell carcinoma (SCC) of the renal parenchyma represents an exceptionally rare malignancy. We present an SCC case demonstrating renal pelvis invasion, histopathologically confirmed following radical nephrectomy. Postoperative adjuvant chemotherapy was initiated, with subsequent development of pulmonary and adrenal metastases at the 10th-month follow-up. After treatment adjustment, the patient is currently 12 months after the operation and is in good general condition. This case illustrates that a definitive diagnosis of primary renal parenchymal SCC remains achievable despite concomitant renal pelvis involvement, emphasizing the importance of comprehensive histopathological evaluation in such rare presentations.

1 January 2016
Verified
Journal Article
Closed access
QCQingke Chen
Qingke Chen
JLJiumin Liu
Jiumin Liu
ZXZhiyong Xian
Zhiyong Xian
ZXZhan Xu
Zhan Xu
YLYaoXiong Luo
YaoXiong Luo
CYChujin Ye
Chujin Ye